(Q37850456)

24 August 2017

1 reference

title

Epigenetic regulation in myelodysplastic syndromes: implications for therapy (English)

1 reference

24 August 2017

2

1 reference

24 August 2017

17

Fortunato Morabito

1 reference

24 August 2017

4

Massimo Gentile

1 reference

24 August 2017

Ernesto Vigna

1

1 reference

24 August 2017

Antonio Madeo

3

1 reference

24 August 2017

Sabrina Bossio

5

1 reference

24 August 2017

Carla Mazzone

6

1 reference

24 August 2017

Eugenio Lucia

7

1 reference

24 August 2017

Lucio Morabito

8

1 reference

24 August 2017

Vincenzo Gigliotti

9

1 reference

24 August 2017

Laura De Stefano

10

1 reference

24 August 2017

Nadia Caruso

11

1 reference

24 August 2017

Pasquale Servillo

12

1 reference

24 August 2017

Stefania Franzese

13

1 reference

24 August 2017

Filippo Fimognari

14

1 reference

24 August 2017

Maria Grazia Bisconte

15

1 reference

24 August 2017

Carlo Gentile

16

1 reference

24 August 2017

language of work or name

English

0 references

publication date

8 March 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

1 reference

24 August 2017

20

1 reference

24 August 2017

4

1 reference

24 August 2017

465-493

1 reference

Proposals for the classification of the myelodysplastic syndromes

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Heterochromatin and epigenetic control of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Chromatin in pluripotent embryonic stem cells and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Stability and flexibility of epigenetic gene regulation in mammalian development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Active DNA demethylation: many roads lead to Rome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Epigenetic regulation of normal and malignant hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Alterations of DNA methylation in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Comprehensive methylome map of lineage commitment from haematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Epigenetics and human disease: translating basic biology into clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Histone modification therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Linking DNA methylation and histone modification: patterns and paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Genomic studies to explore self-renewal and differentiation properties of embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Stem cells: from epigenetics to microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Hereditary cancer: two hits revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Gene silencing by DNA methylation in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Role of histone deacetylases in acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

MicroRNAs and cancer--new paradigms in molecular oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Silencing of microRNAs in vivo with 'antagomirs'

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

LNA-mediated microRNA silencing in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Genetic unmasking of an epigenetically silenced microRNA in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Epigenetic activation of tumor suppressor microRNAs in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Therapeutic options for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Incorporating novel agents in the treatment of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Decitabine--bedside to bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Biological effects of 5-azacytidine in eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Histone deacetylase inhibitors: insights into mechanisms of lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Valproate induces replication-independent active DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Histone deacetylase inhibitors and anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Vorinostat in solid and hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Cyclical DNA methylation of a transcriptionally active promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Acquired mutations in TET2 are common in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

DNA methylation and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

Myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.559164

10.1517/13543784.2011.559164

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference